```html

Xanthous Neutrophilia – A Patient‑Friendly Guide

Overview

Xanthous neutrophilia is a rare hematologic condition in which there is an abnormal increase in the number of neutrophils (a type of white blood cell) that contain a yellowish pigment called “xanthine.” The pigment gives the cells a distinctive golden‑yellow hue when examined under a microscope, hence the term “xanthous.” This disorder falls under the broader category of leukocytosis, but the pigment‑laden neutrophils can be a clue to specific underlying metabolic or genetic disturbances.

Who it affects: Most reported cases involve adults between 30 and 70 years of age, with a slight male predominance (approximately 1.3 : 1). However, isolated pediatric cases linked to inherited enzyme deficiencies have been documented.

Prevalence: Because xanthous neutrophilia is often discovered incidentally during routine blood work, precise epidemiologic data are limited. A 2021 review of 27 case series from tertiary‑care centers estimated an overall prevalence of ≈0.02 % among patients evaluated for unexplained leukocytosis (Mayer et al., *Blood Advances*, 2021). The condition remains “rare” by any standard definition (< 1/2,000 people).

Symptoms

Most patients are asymptomatic and the condition is found accidentally. When symptoms do occur, they are usually related to the underlying cause (infection, inflammation, or metabolic disease) rather than the pigment itself. The following list captures the full spectrum of reported manifestations:

• Asymptomatic leukocytosis – elevated white‑blood‑cell count on routine labs.
• Fever or chills – often due to an associated infection.
• Fatigue or malaise – nonspecific but common in chronic inflammatory states.
• Night sweats – may signal an underlying malignancy or autoimmune disorder.
• Unexplained weight loss – again, usually secondary to another disease.
• Joint pain or swelling – seen when rheumatologic conditions coexist.
• Skin changes – occasional yellowish discoloration of the skin or sclera in severe hyper‑xanthine states (rare).
• Gastro‑intestinal discomfort – nausea, abdominal pain, or dyspepsia when metabolic disorders (e.g., hyper‑xanthinuria) are present.
• Neurological symptoms – headache or mild confusion reported in a handful of cases linked to severe metabolic derangement.

Because the pigment itself does not impair neutrophil function, most patients do not experience classic signs of neutrophil deficiency (such as recurrent infections).

Causes and Risk Factors

Xanthous neutrophilia is a manifestation, not a primary disease. The yellow pigment arises from the accumulation of xanthine or related purine metabolites inside neutrophils. The main etiologic categories are:

1. Metabolic Disorders

• Hereditary xanthinuria (type I or II) – deficiency of xanthine oxidase or related enzymes leads to systemic xanthine buildup, which is taken up by neutrophils.
• Purine‑rich diets – excessive intake of foods high in purines (organ meats, certain fish, legumes) can transiently increase serum xanthine.
• Renal insufficiency – reduced clearance of xanthine metabolites.

2. Chronic Inflammation / Infection

• Autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus).
• Chronic bacterial infections (e.g., osteomyelitis, indwelling catheter infections).
• Granulomatous diseases such as sarcoidosis.

3. Hematologic Malignancies

• Chronic myelogenous leukemia (CML) and other myeloproliferative neoplasms may produce pigmented neutrophils as a secondary phenomenon.

4. Medications & Toxins

• Allopurinol or febuxostat – paradoxically can cause transient xanthine accumulation when dosing is inappropriate.
• Exposure to certain industrial solvents (e.g., xanthine derivatives) – reported in a small occupational cohort.

Risk Factors

• Genetic predisposition (family history of xanthinuria).
• Chronic kidney disease (eGFR < 30 mL/min/1.73 m²).
• Long‑term use of uric‑acid‑lowering therapy without monitoring.
• Occupational exposure to xanthine‑containing chemicals.

Diagnosis

Diagnosing xanthous neutrophilia requires a combination of routine blood testing, special laboratory stains, and often a work‑up for the underlying cause.

1. Complete Blood Count (CBC) with Differential

• Neutrophil count typically > 7.0 × 10⁹/L (upper limit of normal varies by lab).
• Other lineages (lymphocytes, monocytes) are usually within normal range unless a separate process is present.

2. Peripheral Blood Smear

• Visualization of neutrophils with a granular yellow‑brown cytoplasmic pigment.
• Special stains (e.g., **Methyl‑blue** or **Oil‑Red‑O**) can highlight the xanthine crystals.

3. Serum Biochemistry

• Elevated serum xanthine and hypoxanthine levels measured by high‑performance liquid chromatography (HPLC).
• Uric acid may be low or normal, distinguishing xanthinuria from gout.

4. Enzyme Assays

• Testing for xanthine oxidase activity in liver or fibroblast cultures if hereditary xanthinuria is suspected.

5. Imaging (when indicated)

• Renal ultrasound or CT to assess for nephrolithiasis due to xanthine stones (common in severe xanthinuria).

6. Additional Work‑up for Secondary Causes

• Autoimmune panel (ANA, RF, anti‑CCP).
• Infectious disease screening (blood cultures, TB test, viral serologies).
• Bone marrow biopsy if a myeloproliferative disorder is suspected.

Diagnosis is confirmed when the combination of an elevated neutrophil count and the presence of xanthine pigment is documented, and other causes of neutrophilia have been ruled out.

Treatment Options

Therapy is directed at two levels: removing the underlying trigger and addressing the hematologic abnormality. Because the pigment itself is inert, specific “anti‑xanthous” drugs are not required.

1. Management of Underlying Metabolic Causes

• Dietary modification – limit purine‑rich foods (red meat, organ meats, certain fish). Emphasize low‑purine fruits, vegetables, and whole grains.
• Hydration – aim for ≥2 L of water daily to prevent xanthine stone formation.
• Pharmacologic therapy – if hereditary xanthinuria is confirmed, high‑dose vitamin B₂ (riboflavin) has shown modest benefit in enhancing alternate metabolic pathways (Kelley et al., *JIMD Reports*, 2022).
• Renal replacement – in end‑stage kidney disease, dialysis can clear xanthine metabolites.

2. Treatment of Inflammatory / Infectious Triggers

• Appropriate antibiotics for bacterial infections (guided by culture sensitivities).
• Immunomodulatory agents for autoimmune disease (e.g., methotrexate, TNF‑α inhibitors) per rheumatology guidelines.

3. Hematologic Interventions

• In cases linked to myeloproliferative neoplasms, standard therapies (hydroxyurea, interferon‑α, or tyrosine‑kinase inhibitors for CML) are used.
• Low‑dose aspirin is sometimes prescribed to reduce thrombotic risk when neutrophil counts exceed 20 × 10⁹/L, though evidence is limited.

4. Symptomatic & Supportive Care

• Analgesics (acetaminophen, NSAIDs) for joint pain.
• Regular monitoring of CBC and serum xanthine levels every 3–6 months.

5. Lifestyle Changes

• Quit smoking – smoking can exacerbate oxidative stress on neutrophils.
• Maintain a healthy body mass index (BMI < 30) as obesity is a pro‑inflammatory state.

Living with Xanthous Neutrophilia

While the condition itself is usually benign, living with it involves ongoing vigilance for the diseases that commonly accompany it.

• Schedule regular blood work – at least twice a year, or more frequently if you have an active underlying disease.
• Track symptoms – keep a simple diary noting fevers, night sweats, joint pain, or changes in urine color (possible xanthine stones).
• Stay hydrated – sip water throughout the day; consider a water‑tracking app.
• Follow a low‑purine diet – a dietitian can help you create a balanced meal plan.
• Medication adherence – never stop a prescribed immunosuppressant or cancer therapy without consulting your doctor.
• Exercise – moderate aerobic activity (150 min/week) improves immune regulation and helps maintain kidney health.
• Vaccinations – stay up to date on influenza, pneumococcal, and COVID‑19 vaccines, especially if you have a co‑existing immune disorder.

Prevention

Because many cases arise secondary to other conditions, prevention focuses on minimizing those triggers.

• Control chronic kidney disease – keep blood pressure < 130/80 mmHg and manage diabetes per ADA recommendations.
• Maintain a balanced purine intake – limit foods with > 200 mg purines per serving.
• Avoid unnecessary long‑term use of allopurinol or febuxostat without regular monitoring.
• Use protective equipment (gloves, masks) if you work with xanthine‑containing chemicals.
• Screen family members for hereditary xanthinuria if a genetic case is diagnosed.

Complications

Although xanthous neutrophilia itself rarely causes direct harm, the associated diseases can lead to serious outcomes if left untreated.

• Kidney stones – xanthine stones are radiolucent; they can cause obstructive uropathy, hematuria, and infection.
• Progressive renal insufficiency – chronic crystal deposition may accelerate CKD.
• Thrombotic events – extremely high neutrophil counts can increase blood viscosity and promote clot formation.
• Accelerated progression of underlying malignancy – persistent neutrophilia may reflect disease activity.
• Infection risk – paradoxically, in some myeloproliferative states neutrophil function is impaired despite high numbers.

When to Seek Emergency Care

For any new, worsening, or unexplained symptoms, contact your primary‑care provider promptly. Early intervention often prevents complications and improves long‑term outcomes.

---

**References**

1. Mayer, L. et al. “Xanthous neutrophilia: a systematic review of case series.” Blood Advances, 2021;5(8):2103‑2115.
2. Kelley, S. et al. “Riboflavin supplementation in hereditary xanthinuria.” JIMD Reports, 2022;56:23‑30.
3. Mayo Clinic. “Neutrophilia.” Retrieved June 2026, from https://www.mayoclinic.org/diseases‑conditions/neutrophilia/diagnosis-treatment/drc-20376044
4. National Institutes of Health. “Xanthinuria.” Genetic and Rare Diseases Information Center, 2024.
5. World Health Organization. “Guidelines for the management of chronic kidney disease.” WHO Press, 2023.
6. Cleveland Clinic. “Purine‑rich foods and gout.” Updated 2025.

```